Drug Profile
P 246
Latest Information Update: 30 Aug 2004
Price :
$50
*
At a glance
- Originator Bayer Schering Pharma
- Class Antiplatelets; Vascular disorder therapies
- Mechanism of Action GPIIb-IIIa antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arterial thrombosis
Most Recent Events
- 15 Jun 2004 Discontinued - Preclinical for Arterial thrombosis in USA (unspecified route)
- 23 Sep 1998 No-Development-Reported for Arterial thrombosis in USA (Unknown route)
- 29 Aug 1996 New profile